EICHORCondition: HIV-I · Human Immunodeficiency Virus Type 1 · Prophylaxis · Sponsor: Merck Sharp & Dohme LLC
This study will evaluate whether oral islatravir (ISL) is effective in preventing Human Immunodeficiency Virus Type 1 (HIV-1) infection in women at high-risk for HIV-1 infection. The study will compare oral ISL taken once a month with standard-of-care medication for prevention of HIV-1 infection, emtricitabine/tenofovir disoproxil (FTC/TDF), taken once per day. The primary hypothesis is that oral ISL is more effective than FTC/TDF at reducing the incidence rate per year of confirmed HIV-1 infections.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham-UAB Sexual Health Research Clinic (SHRC) ( Site 0064) | Birmingham, Alabama, United States | — |
| MedStar Health Research Institute (MedStar Physician Based R-MedStar Washington Hospital Center ( Si | Washington D.C., District of Columbia, United States | — |
| University of Miami Miller School of Medicine-Infectious Disease ( Site 0076) | Miami, Florida, United States | — |
| Orlando Immunology Center ( Site 0068) | Orlando, Florida, United States | — |
| Ponce De Leon Center Grady Health ( Site 0066) | Atlanta, Georgia, United States | — |
| The University of Mississippi Medical Center ( Site 0065) | Jackson, Mississippi, United States | — |
| KC CARE Health Center-Clinical Trials ( Site 0059) | Kansas City, Missouri, United States | — |
| Rutgers New Jersey Medical School-Clinical Research Center ( Site 0071) | Newark, New Jersey, United States | — |
| Bronx Prevention Center ICAP ( Site 0062) | The Bronx, New York, United States | — |
| The University of North Carolina at Chapel Hill-Medicine ( Site 0056) | Chapel Hill, North Carolina, United States | — |
| Prisma Health Richland Hospital-Clinical Research Unit ( Site 0069) | Columbia, South Carolina, United States | — |
| Prism Health North Texas, Oak Cliff Health Center ( Site 0070) | Dallas, Texas, United States | — |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04644029